
RESOLUTION OF AVASCULAR NECROSIS WITH INNOVATIVE MEDICAL TREATMENT AVOID HIP REPLACEMENT, DECOMPRESSION, DRILLING







DR. SANJAY AGARWALA

Director Professional Services
D.ORTH, M.S. ORTH(BOM), MCH. ORTH (ENGLAND)
Consultant, Joint Replacement & Orthopaedic Reconstructive Surgery at
P. D. Hinduja Hospital & Breach Candy Hospital, Mumbai.
Clinic at:104B, Sukh Sagar, Opera House, Mumbai - 400 007






















Avascular Necrosis (AVN)



What Happens?

Diminished blood supply to your bones can result in structural failure of the bone, which can lead to collapse and dysfunction of the hip. In medical science this condition is called Osteonecrosis or Avascular Necrosis (AVN). Common sites affected are hip, shoulder, wrist & ankle joint.



Hard Bone Normal bone is hard as wood.



Soft Bone due to AVNBone becomes as soft as a boiled potato



Normal femur head



Collapse of femur head in AVN

Head Collapse

Collapse of the femoral head was observed in 75 % of UNTREATED cases of Avascular Necrosis of the Femoral Head

- Literature suggests that more than 50% of patients with Avascular Necrosis of the femoral head require THR (Total Hip Replacement) within three years of diagnosis. In fact, AVN is the commonest cause of THR in young adults.
- Good news!
 Several of these patients who are on Dr. Agarwala's medical line of treatment MAY NOT require surgery.



Some Truths

- Many patients come for consultation after being advised surgical treatment elsewhere, including stem cell treatment, platelet injections, surgical decompression/forage technique (drilling of the femoral head) and, of course, even hip replacement.
- In majority of these cases, surgical intervention was avoided. **Relief from pain was seen within**3-6 weeks and were freely ambulant.
- This research on bisphosphonate therapy in the management of AVN has paved the way for an economically viable medical mode of treatment of this painful condition. The treatment can postpone/avoid the need for expensive Hip Replacement Surgery
- Patients who do not respond adequately and have persistent complaints are offered surgery, that is Total Hip Replacement.
- Those patients suffering from advanced disease with collapse of the femoral head and arthritis of the joints needed THR (Total Hip Replacement) as the cure.
- HIP REPLACEMENT PATIENTS ARE GENERALLY PERMITTED A FULL RANGE OF MOVEMENT AFTER HIP REPLACEMENT BY DR. SANJAY AGARWALA'S TECHNIQUE.





Internationally Published Facts

- This is the result of over two decades of dedicated research and practice in medical management of AVN by Dr. Sanjay Agarwala. This expertise offers hope for patients with AVN of the hip.
- Dr. Sanjay Agarwala has proposed using bisphosphonates as a repurposed treatment for AVN, since his first publication in the year 2001.
- This approach has proved highly effective in managing this painful & debilitating condition for over 25 years and has been published in 15 international peerreviewed journals.
- This treatment needs to be continued for at least three years in view of the threeyear natural course history of AVN and the established three-year safety profile of bisphosphonate use.
- The published studies done by Dr. Sanjay Agarwala have shown 98% success rate in Stage I, 92% success rate in stage II and 70% success rate in stage III, which is far better than the various studies done in the past which have a success rate of only around 30%.

A Paradigm Shift in Osteonecrosis with Bisphosphonates

A 20-Year Study

Saniar Americals DiCorth's MSCheb's MCh/Corb's and Marank Viscourse tion performed at the Department of Orthopaedics, P.D. Hindaia National Housted and Medic

Background: Bisphosphoniates are proven to be effective in obviating the need for surgion of the femoral head. However, the late onset of pain retief hampens compliance. We pre-outcome of a combination therapy compared with alendrouste-only therapy for the man femoral bead.

Methods: The data of patients diagnosed with osteonecrosis of the femoral head for were introspectively analysed. The first group, the alexidonate treatment group, con-diagnosed from Javany 2001 to Javany 2000 and treated with 10 mg oral advota-going, the contribution residence group, comprised 42 has 358 patients slaggood 2017 and treated with a contribution treatment group, comprised 42 has 358 patients slaggood add once annually for 3 years. Climical assessment was performed using the first (VSI) pairs store, and the children fallow has findingsprise casessment was performed.

Results: In the elendronate treatment group, at a mean follow-up of 129.6 months in not require a surgical procedure, and, in the combination treatment group, at a mean 105 months, 88.9% did not require a surgical procedure. The clinical failure rate of stage it, and 29% for stage it in the elemdronate treatment group, and it was 5% for stage III in the combination treatment group. Patients in the combination treatment improvement in VAS score at 6 weeks (from 7.10 to 3.56) compared with patient

Conclusions: Our study shows that both oral elendronate only therapy as the progression of disease, reduce the rise of cotagos.

Againvals and Yijayvargiya Journal of Orthopaedic Surgery and Research (2019) 14:112

https://doi.org/10.1186/s13018-019-1152-7

RESEARCH ARTICLE

Bisphosphonate combinatio non-femoral avascular necro

injay Agarwala" and Mayank Vijayvargiya

ackground: Avascular necrosis at sites other than fernoral hea sociard of treatment still exists for treating early stages of AVN a late arthritic stage needing surgical intervention. Bisphosph ogression, bone collapse, and the requirement for surgery in idy is conducted to evaluate the response of bisphosphonate

terials and methods: Prospectively collected data of 20 par ted with the combination of oral alendronate 70 mg week veen Jan 2009 to Dec 2015, was

avascular necro

Sanjay R Agarwala, 1 Maya

SUMMARY

'Long COVID-19' can affect different ! present, avascular necrosis (AVN) as a COVID-19' has yet not been documen use of life-saving corticosteroids in C/ we anticipate that there will be a res cases. We report a series of three car developed AVN of the femoral head for COVID-19 infection. The mean of used in these cases was 758 mg (4) oan cumulative d

Treatment plan

MANAGING AVN WITH BISPHOSPHONATES A COMPREHENSIVE GUIDE



ALENDRONATE tablet **35mg** to be taken **twice weekly** (e.g. Monday & Thursday).

It is recommended that this tablet is taken in the morning, **even before** brushing your teeth, **on an empty stomach**, with two glasses of water (tea, coffee or juice WILL NOT do).

Do not eat or drink for up to half an hour after taking the tablet as it will change the acidity of the stomach and prevent the activity and absorption of the tablet.

At the end of 30 minutes, the medicine will have been absorbed and normal activities may be resumed.



Alendronate is now available as 35mg and 70mg preparation. **35 mg twice a week works better** than 70mg weekly in AVN cases.



To ensure immediate and sustained blood levels of bisphosphonates for enhanced efficacy, a primary **infusion** of **5mg Zoledronic Acid** injection is also administered intravenously **over 45-60 minutes** to supplement the availability of the drug in the blood at the start of the therapy.



After receiving the slow infusion of Zoledronic, patients may experience fever, flu-like symptoms, bone pain, and body aches for a day or two. These reactions are minimized by

- 1 Slow infusion
- 2 A dose of two tablets of 10 mg **Wysolone** (Prednisolone) taken immediately prior to the infusion & 2 more tablets taken 30 mins after the infusion.
- Symptoms can also be managed with <u>Paracetamol</u> (Crocin 500mg tablets or <u>Combiflam</u>) taken 2-3 times a day for 2 to 3 days.



An additional **BOOSTER infusion of Zoledronic acid** may be advised, to enhance the level of medicine in blood, if the patient does not respond adequately to the standard protocol of bisphosphonate therapy within six weeks.


This helps to potentiate the effects of this medicine.



While on treatment we advise that high impact exercise/physiotherapy be avoided.

These can cause collapse of the soft bone, which would then need surgical intervention like Total Hip Replacement (THR).

Once pain settles **Swimming**, **Walking in a swimming pool**, **Yoga and stationary Cycling** could be safe forms of exercise.



Collapse of softened bone due to impact

Femoral Head

SOFT BONE COLLAPSES WITH EXERCISES. HENCE, AVOID HIGH IMPACT EXERCISES.

AFTER HIGH IMPACT EXERCISE

BISPHOSPHONATE TREATMENT CONVERTS YOUR SOFT BONE INTO A HARD BONE.

FAQ's of Bisphosphonate Therapy:



Is this therapy safe?

Yes, our research, as published in the Journal of Global Oncology (see references), supports this treatment approach. In 20 years of experience, no major side effects have been faced.

What about exercise, physiotherapy and use of walking aids?

While on treatment we advise patients to avoid high impact exercise or rigorous physiotherapy, which can cause collapse of the soft bone. Use walking aids like crutch supports in both arms or a walking stick on the side opposite to the painful side to reduce pressure on the hip.

Do I need to take any specific supplements?

It's crucial to take calcium with vitamin D supplements alongside the treatment for the entire three-year duration, as bisphosphonates do not work in absence of vitamin D and calcium

Can I swim, do yoga and use stationary cycle?

While on treatment we advise that high impact exercise /physiotherapy be avoided. This can cause collapse of the soft bone. Once pain settles **Swimming**, **Walking in a swimming pool**, **Yoga and stationary Cycling** could be safe forms of exercise, which will not negatively impact the soft bone

FAQ's of Bisphosphonate Therapy:

When to book follow-up appointments?

Your appointment will be scheduled after 6 to 8 weeks in the outpatient department from the start of treatment, this may be arranged, earlier or later as necessary.

Will I need any additional tests or investigations on follow up?

Prior to the follow-up appointment, please arrange to have FRESH/NEW X-Rays of your **pelvis with both hips - AP and Frog leg lateral views.**

What can lexpect during follow-up appointments?

After reviewing the new investigations

- A) if the patient is responding well with more than 70% pain relief, oral bisphosphonate therapy will be continued.
- **B)** If not responding adequately, a supplementary early extra booster dose of Zoledronic acid may be recommended

When do you advise for surgery?

We advise surgery for patients who do not respond to bisphosphonate therapy and whose lifestyle, daily activities & quality of life are significantly restricted or hindered by pain.



9


Post Treatment results after 3 years: Case 1



- **A:** X-ray at the first visit showing signs of osteonecrosis (**AVN**) in the femoral head.
- **B:** X-ray at 6 months posttreatment demonstrating **PARTIAL CONSOLIDATION** of the affected bone.
- C: X-ray at 3 years showing COMPLETE STRUCTURAL CONSOLIDATION of the femoral head
- D: Patient at the end of 3 years of treatment, exhibiting a FULL RANGE OF MOTION AND NO FUNCTIONAL LIMITATIONS.

Post Treatment results after 3 years: Case 2









A:X-ray at the first visit showing signs of osteonecrosis (**AVN**) in both the femoral heads.

B:X-ray at 6 months
post-treatment
demonstrating PARTIAL
CONSOLIDATION of the
affected bones.

C:X-ray at 3 years showing

COMPLETE STRUCTURAL

CONSOLIDATION of the
femoral head.

D:Patient at the end of 3
years of treatment,
exhibiting a FULL RANGE
OF MOTION AND NO
FUNCTIONAL LIMITATIONS.

International Publications and Awards



Published: OCT 2021

A Paradigm Shift in Osteonecrosis Treatment with Bisphosphonates

A 20-Year Study

Sanjay Agarwala D(Orth), MS(Orth), MCh(Orth), and Mayank Vijayvargiya, MS(Orth)

Investigation performed at the Department of Orthopsedies, P.D. Hinduja National Hospital and Medical Research Centre, Mumbai, India

Case report

Secondary osteonecrosis of the knee as a part of long COVID-19 syndrome: a case series Published: 2022

Sanjay R Agarwala, Mayank Vijayvargiya, Tushar Sawant



Published : OCT 2022

Bisphosphonates for Post-COVID Osteonecrosis of the Femoral Head

Medical Management of a Surgical Condition

Sanjay Agarwala, MCh(Ortho), Mayank Vijayvargiya, MS(Ortho), Tushar Sawant, DNB(Ortho), and Siddhesh Kulkarni, MS(Ortho) Investigation performed at the Department of Orthopolics, P.D. Hinduja Hospital and Medical Research Centre, Mumbai, India



JOURNAL ARTICLE

Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study

S. Agarwala . D. Jain , V. R. Joshi , A. Sule

Rheumatology, Volume 44, Issue 3, March 2005, Pages 352–359, https://doi.org/10.1093/rheumatology/keh481



Published: AUG 2009

Bisphosphonate Combination Therapy in the Management of Postchemotherapy Avascular Necrosis of the Femoral Head in Adolescents and Young Adults: A Retrospective Study From India

JCO * Global Oncology

An American Society of Clinical Oncology Journal

Original Article

Ann Rehabil Med 2019;43(3):314-320 pISSN: 2234-0645 • eISSN: 2234-0653 https://doi.org/10.5535/arm.2019.43.3.314



Single Dose Therapy of Zoledronic Acid for the Treatment of Transient Osteoporosis of Hip

Sanjay Agarwala, MD, Mayank Vijayyargiya, MD

Department of Orthopedics, P.D. Hinduja National Hospital and Medical Research Centre, Mumbai, India

Case report

BMJ case report

Avascular necrosis as a part of 'long COVID-19'

Sanjay R Agarwala, ¹ Mayank Vijayvargiya, ² Prashant Pandey³









The Editorial Board of

The Journal of the Association of Physicians of India

is pleased to present

The Dr. J. C. Patel - Dr. B. C. Mehta

Best Correspondence Award for the year 2001

Dr. S. Agarwala, Mumbai

For the Correspondence "Study of Mendronate in Avascular Necrosis of Bone" S. Agarwata, A. Safe, B.U. Pai, V.R. Joshi

FE Node; Retail Toylor and Melliot Research Centre, their Sevenire Mag, Maters, Municip (IS) COI. U Acces Physicians India 200; 40:540-561.



Dr. S. K. Bichile Hon. Editor, JAPI.



The use of alendronate in the treatment of avascular necrosis of the femoral head

FOLLOW-UP TO EIGHT YEARS

S. Agarwala, S. Shah. V. R. Joshi

From the P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, India

The use of bisphosphonates in the treatment of avascular necrosis of the femoral head is an encouraging but relatively new option with most published data being derived from small trials with limited follow-up. We present a clinicoradiological analysis of 395 hips with avascular necrosis which were treated with oral alendronate for three years with a mean follow-up of four years (1 to 8).

Our results show an improvement in the clinical function, a reduction in the rate of collapse and a decrease in the requirement for total hip replacement, compared with the findings of other studies in which no treatment was given. This improvement is particularly marked if the treatment is begun in the pre-collapse stages of the disease. Even in Ficat stage-III hips some benefit was obtained from treatment with alendronate by at least a delay in the need for total hip replacement.

The Journal of Arthroplasty Vol. 26 No. 7 2011

Ten-Year Follow-Up of Avascular Necrosis of Femoral Head Treated With Alendronate for 3 Years

Sanjay Agarwala, MS (Orth), MCh (Orth),* and Satyajit B. Shah, MS (Orth)†

Aganwala and Vijayvangiya Journal of Orthopoedic Surgery and Research (2019) 14:112 https://doi.org/10.1186/s/3018-019-1152-7

Journal of Orthopaedic Surgery and Research

RESEARCH ARTICLE

Open Access

Bisphosphonate combination therapy for non-femoral avascular necrosis



Effect of Zoledronic Acid and Alendronate on Bone Edema and Pain in Spontaneous Osteonecrosis of the Knee: A New Paradigm in the Medical Management*

Efeito do ácido zoledrônico e do alendronato no edema ósseo e dor na osteonecrose espontânea do joelho: Um novo paradigma no manejo médico

Sanjay Agarwala 10 Lokesh Sharoff 1 Naeem Jagani 1

¹ Hinduja Hospital and Medical Research Centre, Mumbai, India Rev Bras Ortop

Address for correspondence Sanjay Agarwala, MS, Hinduja Hospital and Medical Research Centre, Mumbai, 400016, India (e-mail: drsa2011@gmail.com).

Sanjay Aganwala* and Mayank Vijayvangiya



















Surgical Attachments:

P. D. Hinduja National Hospital

Veer Savarkar Marg, Mahim, Mumbai - 400 016. Call Centre No. for Appointments: +91 (22) 4510 8181 or +91 (22) 6766 8181 Secretary: +91 22 69248185

Assistance for Appointments: +91 22 6924 8173 Emergency No. +98694 46644 (Whatsapp Only)

Breach Candy Hospital

Bhulabhai Desai Road, Mumbai - 400 026

Dr. Sanjay Agarwala

Head - Orthopedics & Traumatology Director-Professional Services P.D. Hinduja Hospital & Med.Res.Centre Veer Savarkar Marg, Mahim (West), Mumbai 400 016.



Agarwala Clinic:

104-B, Sukh Sagar Building, 1st floor, Abv. Kobe Sizzlers, N. S. Patkar Marg, (Hughes Road), Opera House, Mumbai - 400 007. Contact No. +91 22 35542626 / +91 9869480707

